We investigated the ability of blood B cells, bone marrow (BM) plasma cells, and terminal leukemic plasma cells (T-PCL) from patients with multiple myeloma (MM) t o migrate on extracellular matrix proteins. Hyaluronan (HA), but not collagen type 1, collagen type IV, or laminin, promoted migration of MM blood B cells, as determined by time-lapse video microscopy. Between 13% and 20% of MM blood B cells migrated on HA with an average velocity of 19 pm/ min, and greater than 75% of MM blood B cells exhibited vigorous cell movement and plasma membrane deformation, as did circulating T-PCL and extraskeletal plasma cells from patients with MM. In contrast, plasma cells obtained from BM of patients with MM lacked motility on all substrates tested and did not exhibit cell membrane protrusions or cellular deformation. The interaction of tumor cells with extracellular and cellular components is, therefore, relevant not only to tumor cell growth, but also to metastasis.
The interaction of tumor cells with extracellular and cellular components is, therefore, relevant not only to tumor cell growth, but also to metastasis.
Multiple myeloma (MM) is characterized by malignant plasma cells in the bone marrow (BM), but plasma cells are infrequent in the peripheral b l~o d ,~,~ except during the terminal phases of disease. The presence of multiple bone lesions at various, and often distant, sites throughout the BM of myeloma patients suggests the existence of one or more migratory populations within the malignant clone that must, at some stage, be located in the blood. In myeloma, circulating B cells with IgH VDJ rearrangements identical to those of autologous BM plasma cells have been that have extensive DNA aneuploidy suggestive of malignant status.lO." In addition, circulating B cells in MM patients express receptors required to traverse endothelial cell barriers and interact with ECM pr~teins,'~-'~ whereas BM-localized plasma cells in MM express significantly fewer such receptors." The aim of this study was to characterize the behavioral characteristics of B lineage cells in myeloma to determine which subsets of B or plasma cells in MM are potentially able to migrate between BM sites.
Hyaluronan (HA), a glycosaminoglycan present within the ECM, has been shown to play a fundamental role in cell differentiation and m~tility.'~.'~ HA interacts with several cell-surface receptors including CD44,I7-*' CD38,23 intercellular adhesion molecule (I-CAM):4 and receptor for HAmediated motility (RHAMM).Z5. 26 In particular, RHAMM has been shown to underlie fibroblast migration through the initiation of protein tyrosine phosphorylation events leading to cytoskeletal rearrangement, focal adhesion turnover, and participated in HA-binding, indicating their expression ex vivo in an activated conformation. In contrast, for the majority of BM plasma cells in the majority of patients with MM, expression of RHAMM or CD44 was not accompanied by HA binding. A minority of patients did have HA-binding BM plasma cells, involving both RHAMM and CD44, as evidenced by partial blocking with monoclonal antibodies (MoAbs) t o RHAMM or t o CD44. Despite HA binding by both RHAMM and CD44, migration of MM blood B cells on HA was inhibited by anti-RHAMM but not by anti-CD44 MoAbs, indicating that RHAMM but not CD44 mediates motility on HA. Thus, circulating B and plasma cells in MM exhibit RHAMM-and HA-dependent motile behavior indicative of migratory potential, while BM plasma cells are sessile. We speculate that a subset(s1 of circulating B or plasma cells mediates malignant spread in myeloma.
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the destabilization of cell adhe~ion.'~ While RHAMM is absent from most normal tissues in vivo as well as from confluent cultured cells, RHAMM expression is upregulated in ras-transformed fibroblasts," malignant B cells including MM B cells, activated thymocytes, and cells responding to injury.29 The increased expression of RHAMM on these cell types correlates with increased cell motility, a process inhibited by anti-RHAMM monoclonal antibodies (MoAbs). 26 We have analyzed the ability of B-lineage subsets from blood and BM of MM patients to undergo behavioral changes associated with cell migration including cell deformation and motility. Here we report that subsets of MM blood B cells and circulating terminal leukemic plasma cells (T-PCL) exhibit FZHAMM-dependent motility on HA, but not on substrates of fibronectin, collagen type I, collagen type IV, or laminin. In contrast, BM-localized plasma cells do not exhibit motile behavior on any substrate examined.
and was conjugated to fluorescein isothiocyanate (FITC)?' CD44 MoAb 3C12 and MoAb 50B4 were gifts from Dr G. Dougherty (University of British Columbia, Vancouver) and Dr M. Letarte (University of Toronto, Toronto, Canada). The anti-RHAMM MoAbs 3T3.5 and MSV10-6 have been previously described.'* Leul7-PE (CD38) and Leul5-PE (CDI Ib) were purchased from Becton Dickinson (San Jose, CA), and OKTlO was obtained from the American Type Culture Collection (Rockville, MD). MoAb isotype controls (IgGl, IgG2, IgG2-PE, IgG1-FITC), goat anti-mouse-PE, and avidin-FITC were obtained from Southem Biotechnologies Associates (Birmingham, AL). Streptomyces hyaluronidase was obtained from Calbiochem (San Diego, CA).
96-well tissue culture plates were coated with the following ECM proteins and used for adhesion assays. Plasma fibronectin (Sigma, St Louis, MO) was diluted in phosphatebuffered saline (PBS) and plated at final concentrations of 10 pgl mL, 25 pg/mL, and 50 pg/mL. Collagen type I (Sigma) and collagen type IV (Sigma) were diluted in PBS and plated at final concentrations of 25 pg/mL, 50 pg/mL, and 100 pg/mL. Healon (sodium hyaluronate; Pharmacia LKB Biotechnology, Uppsala, Sweden) was added to culture wells at a final concentration of 100 pg/mL. Laminin was added to wells at a final concentration of 10 pglmL or 20 pg/mL. Wells containing ECM were air-dried overnight at room temperature and stored at 4°C until use. Wells were rinsed in PBS before use in motility assays.
Venous blood from 37 patients with MM, three patients with B chronic lymphocytic leukemia (B-CLL), and six normal donors was collected into heparinized vacutainer tubes. After centrifugation over a ficoll-hypaque gradient, the interface containing peripheral blood mononuclear cells (PBMC) was collected and washed twice in PBS. PBMC isolated as above were sorted for CD19-positive cells using a Coulter ELITE flow cytometer (Coulter, Hialeah, FL). PBMC were resuspended in cold RPMI at 1 X 10' cells per well and stained with preservative-free FMC63-FITC at 4°C for 1 hour. After the incubation, the cells were washed twice with cold PBS and resuspended in cold RPMI supplemented with 1% fetal calf serum (FCS) in preparation for cell sorting. Electronic gates were set on those FMC63-FITC (CD19)-positive cells that showed staining above the isotype-matched (IgG2a) control. For the patients with MM studied here, the percentage of B cells in the peripheral blood ranged from 3% to 50%. FMC63-FITC-stained cells were kept cold during the sorting procedure with ice packs, and cells were sorted in PBS rather than in sheath fluid. Sorted cells were immediately pelleted and resuspended in cold RPMI without FCS or bovine serum albumin (BSA) and kept on ice until used in the motility assay. Sorted cells maintained in this manner were viable throughout the motility assay as determined by trypan blue exclusion. Of sorted CD19' blood cells cultured on HA, 90% to 100% expressed a moderate density of cytoplasmic Ig and contained less than 1/10' detectable plasma cells and 1% plasmacytoid cells, as determined by Wright staining. After culture on HA, sorted B cells displaying ruffled membranes were all cIg+ as determined by confocal microscopy.
BM aspirates were obtained from 12 patients with MM and collected into heparinized tubes. Mononuclear cells, isolated by centrifugation over a ficoll-hypaque gradient, were collected and washed twice in PBS. Plasma cells were sorted as either CD19' large cells or CD38h1 large cells; identical results were obtained with either type of sorted plasma cells. For those samples sorted based on CD19, expression of CD38h' was confirmed by staining of replicate aliquots. Replicate samples showed that these sorted BM plasma cells all expressed strong cytoplasmic immunoglobulin staining, but had no ruffled membranes when cultured on HA. In some cases, unstained BM samples were sorted for cells with high scatter properties, confirmed as plasma cells in replicate samples; these plasma cells, which were unexposed to antibody, were comparable with cells sorted by Preparation ofEC.44~.
Cells.
surface markers on all assays described here. Sorted cells were obtained and prepared for motility assays as indicated above. Pleural effusions (n = 3) were obtained from two patients with MM at the terminal stage of disease. Pleural effusion (PE) samples contained greater than 98% plasma cells as determined by morphology (Giemsflright stain) and by their PCA-I '38h'cIgh' phenotype.
Splenic cells from patients with hairy cell leukemia (HCL; n = 3) and splenic and lymph node B cells from normal donors (n = 3) were put into saline immediately after removal and were then placed in RPMI supplemented with FCS. Tissue fragments were passed through a sieve to produce single-cell suspensions, which were stained with preservative-free FMC63-FITC and sorted for CD 19' B cells as indicated above.
Immunofluorescence. Analysis of surface marker expression on MM cells was performed by two-color immunofluorescence. Briefly, cells were stained with an unconjugated antibody for 45 minutes at 4"C, followed by three washes in PBS containing 1% FCS and 0.002% sodium azide (IF buffer). Goat anti-mouse antibody (Jackson, Westgrave, PA), conjugated to PE, was added at 0.1 pg/mL for 30 minutes at 4°C. Cells were washed twice in IF buffer, and nonspecific Ig binding sites were blocked by addition of mouse serum Ig (1 pg/mL) for 10 minutes at 4°C. Cells were then labeled for CD19 by addition of a second antibody conjugate, FMC63-FITC for 20 minutes at 4"C, followed by three washes in IF buffer and fixation in I % formalin. Samples were analyzed on a FACScan (Becton Dickinson). Files of 10,000 events were collected and were electronically gated for CD19 relative to an IgG2a isotype control. In all cases, staining with a specific MoAb was compared with the appropriate isotype-matched control.
Blood B cells, T-PCL, BM-derived plasma cells, and PE plasma cells, sorted as described above, were analyzed for their ability to migrate on ECM substrates. Preparation of ECMcoated wells is described above. Varying dilutions of HA ranging from 50 pg/mL to 3 pglmL were added directly to MM cells in culture medium to determine the concentration of HA that maximally stimulates cell motility. A concentration of 100 pg/mL was optimal at promoting motility, and this concentration was used in all experiments. To ensure that the migration observed was, indeed, HAdependent, HA substrates were treated with 5OTBU S hyaluronidase at 37°C for 30 minutes followed by three washes with PBS, before addition of cells. Pretreatment with S hyaluronidase abolished cell migration on HA substrates. For MoAb blocking experiments, cells were pretreated with anti-RHAMM MoAb 3T3.5 or anti-CD44 MoAbs 3C12 or 50B4 for 30 minutes at 4°C before motility assays. During motility assays, temperature was maintained at a constant 37°C using a custom-made computer-controlled heating chamber placed on the microscope stage. Cell migration assays were performed in 96-well plates coated with various ECM proteins, as indicated above. In some instances, motility experiments were performed under conditions of fluid shear flow created by a constant air current; the percentage of cells migrating and cell velocity were identical to the values obtained under static conditions. Cell locomotion was recorded by timelapse video microscopy using an inverted-phase contrast microscope adapted with a high resolution 35-mm video camera and s-VHS video recorder. Video recordings were displayed and analyzed using a computerized image analysis with custom-designed software developed at the University of Alberta (Edmonton, Canada). Frames of video images were captured and digitized by the computer with a Creative Labs VideoBlaster overlay device. To measure cell displacement, the screen x and y coordinates of individual cells were tracked over time, followed by calculation of cell velocity as micrometers per minute. Cell deformation was defined as those cells with active cell membranes deforming from a round shape. Computerized analysis of cell deformation used software designed to compare the outline of a cell with the outline of a perfect circle, with Motility assay.
Locomotion analysis.
For personal use only. on October 31, 2017. by guest www.bloodjournal.org From larger values indicating increasing deviation of the cell membrane from a circle. A perfect circle has a theoretical value of 0. However, because there is an inherent error in measuring the x and y coordinates, only values above 0.5 were considered as indicating cell membrane deformation, and values 50.5 were considered nondeforming. For each sample, a minimum of 100 cells were tracked for 90 minutes and analyzed at 2 to 4-minute intervals.
HA conjugated to FITC was prepared as de~cribed.~' An HA-FITC preparation was titered against MM blood B cells to obtain the optimal working concentration of 125 pg/mL. MM peripheral blood cells or BM cells in RPMI were incubated with HA-FITC at room temperature for 30 minutes, and HA-FITC binding was determined by flow cytometry, in comparison with unstained cells, avidin-FITC, and IgG-FITC as negative controls. In MoAb blocking studies, cells were pretreated with 10 pLpl mL anti-RHAMM MoAb 3T3.5 or 5 pg/mL anti-CD44 MoAb 3C12 for 30 minutes at 4°C. Binding of fluoresceinated HA was identical at 4°C and room temperature, and MoAbs against CD44 or RHAMM also inhibited identically at both concentrations (not shown). Although binding of HA-FITC at 37°C was identical to 4°C and room temperature, more variability was observed at this temperature. At 37°C in over half of the patients tested, MoAbs to CD44 and RHAMM enhanced rather than inhibited binding of HA-FITC. The addition of 200 pg/mL unlabeled HA, but not 200 pg/mL heparin, to cells at the same time as HA-FITC reduced HA-FITC binding. After preblocking incubation with MoAbs, HA-FITC was added to cells for 30 minutes at the various temperatures, followed by two washes in PBS. MM peripheral blood samples were then incubated with Leul5-PE (CDI lb), followed by two washes in PBS, and resuspension of cells in 1% formalin for analysis. Because Sorted CD19+ MM blood B cells were cultured with 100 pg/mL HA in single-chamber cultures slides (NUNC) for 60 minutes at 37°C with 5% CO2. Cells were permeablized in ethanol, followed by fixation in 1% formalin, and were stained for distribution of RHAMM or CD44 using the anti-RHAMM MoAb MSV10-6 or anti-CD44 MoAb 50B4. MoAbs were added to the cells for 1 hour at 4°C. After the incubation, goat antimouse-PE was added, followed by three gentle washes in PBS. Cells were mounted in 100% glycerol, and immunofluorescent images were captured by laser confocal microscopy (Leica, Heidelberg, Germany).
MM peripheral blood B cells or BM plasma cells were cultured with 100 pg/mL Healon on thermolyte coverslips at 37°C with 5% CO2 for 1 hour. Cells were fixed at room temperature by incubation in 2.5% glutaraldehyde for 1 hour. After fixation, coverslips with attached cells were postfixed in 1% OsO, in PBS, followed by treatment in 1% tannic acid. Cells were subjected to an additional postfixation step in 1% OsO,, followed by dehydration in graded ethanol.
Binding of Juoresceinated HA.
Laser confocal microscopy.
Scanning electron microscopy.

RES U LTS
To evaluate their migratory behavior, we analyzed the ability of sorted blood B cells and MM BM plasma cells to migrate on various M M blood B cells are motile on HA. Sorted MM blood B cells were analyzed for their ability to migrate on various ECM proteins. The 96-well plates were coated with 100 pg/mL of fibronectin, collagen type I, collagen type IV, laminin, or HA, and migration was analyzed as indicated in Materials and Methods. Concentrations of fibronectin, collagen type I, collagen type IV, and laminin ranging from 50 pg/mL to 500 pg/mL gave identical results to those indicated above. Although the percent of migrating cells was low for cells placed on fibronectin or collagen, for those few cells, the velocity of locomotion was equivalent to that on HA.
ECM proteins including fibronectin, collagen type IV, collagen type I, laminin, and HA. Peripheral blood and BM samples obtained from patients with MM were sorted on the basis of either CD19+ expression (blood B cells) or CD19+/ high scatter (BM plasma cells confirmed in replicate samples to be CD38hi). Of the ECM proteins tested, only HA was found to efficiently promote motile behavior in MM blood B cells (Table 1) . Motile B cells were detected at comparable numbers in untreated patients, those on chemotherapy, and those off treatment.
MM blood B cells displayed random migration and cell membrane deformation when cultured on HA, as determined by video time-lapse microscopy (Fig 1) . Blood B cells were analyzed for physical displacement at 0, 7, and 15 minutes after initiation of migration on HA. Figure 1A (Table I) , with an average velocity of 19 p d m i n ( Table 2) . whereas less than 5% of cells were motile on other ECM proteins (Table 1 ). In contrast with MM blood B cells, less than 5% of CD19+ B cells from normal blood, spleen, or lymph node exhibited motile behavior or cell deformation on any substrate examined, including HA (Table 2) .
Scanning electron microscopy analysis of MM blood B cells indicated that a subset of myeloma blood B cells cultured on HA exhibited polarized membrane ruffling, while other cells exhibited attachment by a single pseudopodia or tether (Fig 2) . This apparent tether was also detected in video time-lapse analysis, where MM blood B cells that were actively deforming (75%), although classed as non-motile based on their minimal positional change over time, were visually highly active on HA but tethered (not shown). Tethering was not seen for BM plasma cells or for B cells from normal donors.
To evaluate the relative extent and speed of motility, the behavior of MM blood B cells was compared with other types of malignant B cells. HCL splenic B cells were motile on HA, although at a slower average velocity (5 pdmin 
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M M blood B cells or plasma cells derived from BM, PE, or blood of patients with terminal MM, (T-PCL) were analyzed for their ability to migrate or deform on HA using time-lapse video microscopy, as described in Materials and Methods. Values are the means 2 SD. Cell deformation was determined visually by observing images of individual cells followed over a 90-minute period. HCL splenic B cells and B cells from normal blood, spleen, and lymph node were isolated as described in Materials and Methods, and their velocity on HA and cell deformation were determined as described above and in Materials and Methods. The motility and deformation of normal B cells were similar for all tissue origins.
A value of s0.5 represents the error in repeated measurements of a circle and, thus, designates a nondeforming cell. . :c HA or other ECM substrates examined (Tables 2 and 3 ). In contrast with BM-derived plasma cells. a large proportion of circulating T-PCL cells derived from either peripheral blood or pleural effusions of terminal MM patients were highly motile on HA, with an average velocity of IS pm/min (Table 2) , and the equivalent number of cells also exhibited extensive cell membrane deformation (Table 2 ). For several of these patients, behavioral properties of plasma cells from BM were compared with peripheral plasma cells from PE than that observed for MM blood B cells (Table I) , consistent with our previous observations." Furthermore, the degree of cell deformation, as measured by the number and extent of cell membrane protrusions, was not as extensive as that observed with MM blood B cells ( Table 2) . Tethering of active cells was not apparent in HCL. B cells isolated from peripheral blood of patients with chronic lymphocytic leukemia (CLL) were nonmotile, nondeforming cells without apparent tethers (Table 2) .
BM plasma cells are sessile, but T-PCL and P E plasma cells are motile on HA. In contrast with the migratory behavior of MM blood B cells on HA, MM BM-derived plasma cells were not motile on HA substrates ( Table 2) . MM plasma cells appeared as sessile cells that did not exhibit any cell protrusions or undergo any cell deformation on or blood, collected from the patient within the same hour. Analysis by video time-lapse microscopy showed that while the BM-derived plasma cells were consistently sessile, PEderived or blood T-PCL cells were motile on HA (Table 3) .
MM blood B cells and BM plasma cells express multiple
HA receptors. We examined the expression of HA receptors on MM blood B cells, as well as on BM-derived or PEderived plasma cells. Multiple HA binding receptors have been described and include CD44, RHAMM, ICAM-1, and CD38. Flow cytometry analysis of MM blood B cells indicated that greater than 80% of cells strongly expressed CD44 and also expressed a moderate to high intensity of RHAMM and CD38 (Table 4) . No significant differences in CD44 or RHAMM expression were observed between untreated patients, patients on treatment, or patients off chemotherapy (data not shown), although the percentage of CD19fCD38hi cells present within peripheral blood of individual patients varied during chemotherapy. ' Flow cytometry analysis of MM BM-derived plasma cells confirmed the expression of RHAMM, CD44, and CD38 (Table 4) . Others have shown the presence of ICAM on BM plasma ~e l l s .~~,~~ T-PCL cells from MM patients also strongly expressed RHAMM, CD44, and CD38 (Table 4) . (Table  5) . To determine the role of RHAMM and CD44 in HA binding to myeloma cells, MM blood B cells or BM plasma cells were preincubated with antibodies against RHAMM or CD44. The anti-CD44 MoAbs 3C12 and 50B4 are known to block HA binding.34235 HA-FITC binding to MM blood B cells involved both RHAMM and CD44, as HA-FITC binding was reduced up to 50% after preincubation of cells with MoAb 3T3.5 (anti-RHAMM) and up to 80% after preincubation with MoAbs 3C12 or 50B4 (anti-CD44) ( Table 5 ). Pretreatment of blood B cells with both 3T3.5 and CD44 did The analysis of motile behavior was as described for Table 2 In contrast with blood B cells, BM-derived plasma cells from 7 of 12 patients did not bind HA-FITC (Table 5) , despite their surface expression of HA receptors. BM plasma cells from 5 of 12 patients with MM bound HA weakly or moderately, and HA binding was inhibited predominantly by MoAbs against CD44 ( Table 5 ) , suggesting that in these cases, CD44 is the major HA binding receptor. For B cells derived from normal donors, HA binding was inhibited by MoAbs against CD44 but not by MoAbs against RHAMM (not shown), consistent with their CD44+ RHAMM-phenotype."
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Motility of blood B cells on HA requires RHAMM but not CD44. To determine the involvement of RHAMM or CD44 on HA-mediated MM blood B-cell motility, we performed blocking studies with anti-CD44 MoAbs known to block HA binding3',32 and with an anti-RHAMM MoAb shown to block fibroblast motility." Preblocking MM cells with anti-RHAMM MoAb reduced the motility of blood B cells by 80% and of PE-derived plasma cells by 98%, but did not modulate the nonmotile behavior of BM-derived plasma cells (Table 6 ). In contrast, anti-CD44 MoAbs 3C12 and 50B4 did not affect the motility of MM blood B cells or PE-derived plasma cells (Table 6 ). The motility of HCL B cells on HA was also inhibited by the anti-RHAMM MoAb 3T3.5, but not by the anti-CD44 MoAb 3C12 (data not shown). This indicates that RHAMM, but not CD44, is central to the motile behavior of malignant B cells.
Migration of cells on ECMs involves the assembly and disassembly of focal contacts, and many receptors involved in cell migration can be localized to focal adhesions at the leading edges of migrating ~e l I s .~~-~* To further examine the role of HA receptors in the migratory response of MM blood B cells cultured on HA substrates, we examined the distribution of RHAMM and CD44 on blood B cells by laser confocal microscopy. On most blood B cells, RHAMM was found to be localized to the ruffled edges of the cell membrane (Fig 3A) . CD44 displayed diffuse cell membrane distribution in all MM blood B cells examined (Fig 3B) .
In contrast with the pattern of RHAMM redistribution to the ruffled membranes by HA-exposed MM blood B cells, after exposure to HA, BM plasma cells had a paranuclear distribution of RHAMM with only diffuse membrane staining, suggesting internalization of RHAMM (Fig 3C) . As was seen for B cells, CD44 did not undergo redistributed on or in BM plasma cells, remaining evenly distributed on the outer cell membrane (Fig 3D) . Ras is implicated in the upregulation of RHAMM expression." as well as in the upregulation of cell migration,'h and may play an important role in RHAMM-mediated migration of MM B cells. Experiments are ongoing to investigate the roles of RHAMM and ras in MM B-cell motility.
Normal murine fibroblasts express multiple RHAMM isoforms that occur on the plasma membrane, within the cytoplasm or secreted." Molecular evidence suggests the expression of novel RHAMM isoforms in MM (L.M.P. et al. unpublished data). As RHAMM is expressed on motile blood B cells and circulating T-PCL cells. as well as on sessile BM plasma cells. it is intriguing to speculate that RHAMMmediated motility may depend on cell type-specific expression of a particular RHAMM isoform. Altematively, as cellassociated RHAMM promotes motility and cell-free or secreted RHAMM inhibits motility."' an overproduction of secreted RHAMM would be predicted to reduce motile behavior. This may underlie the lack of motility by MM BM plasma cells. The overall avidity of the cell-associated RHAMM for its HA ligand, perhaps controlled by the production of soluble RHAMM isoforms?' may determine its ability to initiate motile behavior. Experiments are in progress to evaluate RHAMM isoform expression. A characteristic of MM blood B cells not found at any stage of normal B-cell differentiation is expression of RHAMM and an increase in motile behavior."."." The absence of RHAMM on normal B cells and its prominent expression on malignant B cells suggests a role in the malignant process. In normal murine fibroblasts, transfection with RHAMM has been shown to be oncogenic and is required for ras transformation.U On migrating fibroblasts, RHAMM has been found to be localized to focal plaques and, furtherFor personal use only. on October 31, 2017. by guest www.bloodjournal.org From more, to be involved in focal adhesion turnover through the initiation of signaling pathways leading to protein tyrosine phosphorylati~n.~~ Our data indicate that RHAMM is localized to the ruffled edges of migrating MM blood B cells. Furthermore, our preliminary work indicates that MoAb modulation of RHAMM on MM blood B cells induces tyrosine phosphorylation distinct from that induced by anti-CD44 MoAbs. Thus, on MM blood B cells, RHAMM appears to play an important role in signal transduction processes, consistent with observations of signaling in the turnover of focal contacts in murine fibrobla~ts.~' In contrast with blood B cells, BM-derived plasma cells express a novel paranuclear distribution of RHAMM after incubation with HA, but weak plasma membrane distribution. The novel distribution of RHAMM after plasma cell incubation with HA may reflect an active process of RHAMM internalization after interaction with HA. The lack of HA binding by BM plasma cells, observed by flow cytometry, appears to reflect an active process of RHAMM-HA interaction leading to internalization of the receptorfiigand complex and consequent loss of surface-bound HA (in preparation). It is intriguing to speculate that the internalization of surface RHAMM by BM plasma cells may ensure their retention within the BM.
Our report shows that plasma cells from peripheral blood of patients with terminal MM were highly motile cells. The infrequent presence of circulating plasma cells in MM patients, at stages of disease before T-PCL:,6 suggests that the CD19+ MM blood cells observed in these studies could include a small subset of circulating plasma cells. However, the motile peripheral blood CD19' subset in MM consisted of mainly small cells that were morphologically distinct from both the nonmotile BM plasma cells and circulating MM plasma cells. The low frequency of circulating plasma cells in myeloma and in our sorted CD19+ population considered together with the morphologic differences and low cIg density distinguishes MM blood B cells from circulating plasma cells. Our previous data indicate that the majority of MM blood B cells express a low to moderate density of monotypic Ig light and that peripheral blood of patients with MM contains clonotypic cells with CDR3 IgH rearrangements identical to the BM plasma c e k 7 A large subset of peripheral blood clonotypic B cells adhere to BM stroma, consistent with expectations for a BM-homing subset (in preparation). Although the relevance of this circulating population to the progression of MM is not yet determined, our work demonstrates that blood-localized B cells in MM have the potential to extravasate from blood and to interact with components of the BM microenvironment.
MM BM plasma cells display a strict dependence on cellcell interactions with BM stroma for their in vitro growth and s~r v i v a l .~~,~~ The sessile nature of BM plasma cells appears to reflect their dependence on BM stroma and consequent downregulation of motile behavior to maintain stromal interactions. Although the mechanism by which apparently sessile BM plasma cells enter circulation in T-PCL are unclear, the presence of motile B cells and T-PCL in circulation likely reflects disease progression towards BM stromal independence. The work presented here indicates that the expression of RHAMM plays a central regulatory role in the motile behavior of circulating B lineage cells in myeloma.
